Neurocrine Biosciences
↗San Diego, USA
Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to discovering and developing life-changing treatments for patients with complex neurological, endocrine, and neuropsychiatric disorders. The company is best known for its successful commercialization of INGREZZA (valbenazine), the first FDA-approved treatment for tardive dyskinesia, which has become a multi-billion dollar product.
In late 2024, the company achieved a major milestone with the FDA approval of Crenessity (crinecerfont) for congenital adrenal hyperplasia (CAH), diversifying its portfolio into rare endocrine diseases. Neurocrine maintains a robust R&D engine with over 15 clinical programs, focusing on high-unmet-need areas such as schizophrenia, major depressive disorder, and movement disorders.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:CNS and Endocrine Therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$2.3B - $2.7B
Founded:1992
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$10M
Investors:BB Biotech, Venrock, International Biotechnology Trust, HBM Healthcare Investments
STOCK
Exchange:NASDAQ
Ticker:NBIX
Market Cap:$13.4B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Ingrezza, Crenessity)
Modalities:Small molecule, VMAT2 inhibitor, CRF1 receptor antagonist, Muscarinic agonist
Active Trials:17
Trial Phases:Phase 1: 5 | Phase 2: 7 | Phase 3: 4 | Phase 4: 1
FDA Approvals:5
EMA Approvals:2
CORPORATE STRUCTURE
Subsidiaries:Diurnal Group plc
Key Partnerships:AbbVie (Orilissa and Oriahnn), Bial (Ongentys), Nxera Pharma / Sosei Heptares (Muscarinic portfolio), Takeda (Psychiatry pipeline), Immedica (Crinecerfont European rights)
COMPETITION
Position:Leader
Competitors:Teva Pharmaceuticals (Austedo), Sage Therapeutics, Acadia Pharmaceuticals, Intra-Cellular Therapies, Jazz Pharmaceuticals
LEADERSHIP
Key Executives:
Kyle Gano - CEO
Matt Abernethy - CFO
Sanjay Keswani - CMO
Scientific Founders:Kevin Gorman, Wylie Vale, Lawrence Steinman
Board Members:William Rastetter (Chairman), Kevin Gorman, Kyle Gano, Gary Lyons
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Neurocrine Biosciences. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.